BioNTech mRNA Cancer Vaccine Misses Key Phase 3 Endpoint, Triggering Stock Drop
BioNTech’s phase 3 trial for its mRNA cancer vaccine BNT113 failed to meet a primary endpoint for progression-free survival in head and neck cancer patients. Despite this setback, the company will continue the study to assess overall survival, as the independent data monitoring committee recommended. The news caused BioNTech’s stock to fall 5% in premarket trading, reflecting reduced analyst confidence in the drug’s ability to extend life, though some experts note that immune responses may take time to develop.